Symbols / CLYM Stock $10.55 -3.30% Climb Bio, Inc.

Healthcare • Biotechnology • United States • NGM
CLYM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, …
Exch · Country NGM · United States
Market Cap 604.12M
Enterprise Value 394.87M
Income -52.79M
Sales —
FCF (ttm) -34.24M
Book/sh 3.10
Cash/sh 2.29
Employees 28
Insider 10d —
IPO Aug 10, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -9.40
PEG —
P/S —
P/B 3.40
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 26.91
Current Ratio 27.86
Debt/Eq 0.32
LT Debt/Eq —
EPS (ttm) -0.77
EPS next Y -1.12
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -21.27%
ROE -30.92%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 57.26M
Shs Float 28.06M
Insider Own 0.37%
Instit Own 66.46%
Short Float 5.16%
Short Ratio 2.23
Short Interest 2.09M
52W High 12.48
vs 52W High -15.46%
52W Low 1.16
vs 52W Low 809.48%
Beta —
Impl. Vol. 2.10%
Rel Volume 1.33
Avg Volume 743.59K
Volume 985.56K
Target (mean) $19.77
Tgt Median $19.00
Tgt Low $15.00
Tgt High $26.00
# Analysts 13
Recom Strong_buy
Prev Close $10.91
Price $10.55
Change -3.30%
About

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.77
Mean price target
2. Current target
$10.55
Latest analyst target
3. DCF / Fair value
$-10.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.55
Low
$15.00
High
$26.00
Mean
$19.77

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 main HC Wainwright & Co. Buy → Buy $20
2026-05-08 main Wedbush Outperform → Outperform $17
2026-05-06 main BTIG Buy → Buy $19
2026-05-05 init Chardan Capital — → Buy $22
2026-04-21 main Oppenheimer Outperform → Outperform $18
2026-04-15 init Mizuho — → Outperform $18
2026-04-08 reit BTIG Buy → Buy $8
2026-03-24 init B. Riley Securities — → Buy $26
2026-03-18 init Truist Securities — → Buy $17
2026-03-11 init Raymond James — → Strong Buy $25
2026-03-10 main HC Wainwright & Co. Buy → Buy $15
2026-03-06 main Wedbush Outperform → Outperform $14
2026-03-06 main Baird Outperform → Outperform $12
2026-03-05 init Wedbush — → Outperform $12
2026-02-13 init Piper Sandler — → Overweight $23
2025-12-30 init Freedom Broker — → Buy $9
2025-12-18 main HC Wainwright & Co. Buy → Buy $11
2025-10-16 init William Blair — → Outperform —
2025-10-16 reit BTIG Buy → Buy $8
2025-10-13 init HC Wainwright & Co. — → Buy $9
News
RSS: Latest CLYM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-26 THOMAS STEPHEN BASIL Director — 50,000 $7.00 $350,253
2026-02-13 THOMAS STEPHEN BASIL Director — 100,000 $5.23 $529,129
2026-01-05 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 7,111 $3.50 $24,888
2025-12-12 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 314,561 $2.18 $754,737
2025-08-07 THOMAS STEPHEN BASIL Director — 100,375 $0.00 $0
2025-06-30 BRENNAN AOIFE M Chief Executive Officer — 20,618 $1.22 $25,154
2025-06-27 BRENNAN AOIFE M Chief Executive Officer — 68,750 — —
2025-06-27 THOMAS STEPHEN BASIL Director — 25,094 — —
2025-06-20 PIMBLETT EMILY Officer — 1,242 $1.24 $1,540
2025-06-18 PIMBLETT EMILY Officer — 5,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
67.88
+123.59%
30.36
-24.62%
40.27
-10.77%
45.13
Research And Development
46.71
+225.84%
14.34
-6.98%
15.41
-41.21%
26.21
Selling General And Administration
21.17
+32.11%
16.02
-35.55%
24.86
+31.41%
18.92
General And Administrative Expense
21.17
+32.11%
16.02
-35.55%
24.86
+31.41%
18.92
Other Gand A
21.17
+32.11%
16.02
-35.55%
24.86
+31.41%
18.92
Other Operating Expenses
—
—
—
—
Total Expenses
67.88
+123.59%
30.36
-24.62%
40.27
-10.77%
45.13
Operating Income
-67.88
-123.59%
-30.36
+24.62%
-40.27
+10.77%
-45.13
Total Operating Income As Reported
-67.88
+17.24%
-82.02
-103.65%
-40.27
+10.77%
-45.13
EBITDA
-67.79
-123.27%
-30.36
+24.62%
-40.27
+10.77%
-45.13
Normalized EBITDA
-67.50
-416.77%
21.31
+152.21%
-40.81
+6.51%
-43.65
Reconciled Depreciation
0.10
0.00
—
—
EBIT
-67.88
-123.59%
-30.36
+24.62%
-40.27
+10.77%
-45.13
Total Unusual Items
-0.29
+99.44%
-51.67
-9739.55%
0.54
+136.12%
-1.48
Total Unusual Items Excluding Goodwill
-0.29
+99.44%
-51.67
-9739.55%
0.54
+136.12%
-1.48
Special Income Charges
0.00
+100.00%
-51.66
0.00
—
Other Special Charges
—
51.66
—
—
Net Income
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Pretax Income
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Net Non Operating Interest Income Expense
8.32
+2.35%
8.13
+76.02%
4.62
+236.00%
1.38
Net Interest Income
8.32
+2.35%
8.13
+76.02%
4.62
+236.00%
1.38
Interest Income Non Operating
8.32
+2.35%
8.13
+76.02%
4.62
+236.00%
1.38
Interest Income
8.32
+2.35%
8.13
+76.02%
4.62
+236.00%
1.38
Other Income Expense
-0.29
+99.44%
-51.67
-9739.55%
0.54
+136.12%
-1.48
Other Non Operating Income Expenses
—
—
—
1.38
Gain On Sale Of Security
-0.29
-3133.33%
-0.01
-101.68%
0.54
+136.12%
-1.48
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Net Income From Continuing Operation Net Minority Interest
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Net Income From Continuing And Discontinued Operation
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Net Income Continuous Operations
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Normalized Income
-59.56
-167.94%
-22.23
+37.66%
-35.66
+18.52%
-43.76
Net Income Common Stockholders
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-0.88
+42.48%
-1.53
-17.69%
-1.30
+24.42%
-1.72
Basic EPS
-0.88
+42.48%
-1.53
-17.69%
-1.30
+24.42%
-1.72
Basic Average Shares
47.77
-1.10%
48.30
+78.97%
26.99
+2.57%
26.31
Diluted Average Shares
47.77
-1.10%
48.30
+78.97%
26.99
+2.57%
26.31
Diluted NI Availto Com Stockholders
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
167.74
-22.77%
217.19
+96.60%
110.47
-18.17%
134.99
Current Assets
105.85
-31.65%
154.87
+40.47%
110.25
-17.96%
134.39
Cash Cash Equivalents And Short Term Investments
101.08
-33.02%
150.92
+41.31%
106.80
-13.57%
123.57
Cash And Cash Equivalents
35.69
-59.09%
87.23
-6.32%
93.11
+113.63%
43.59
Cash Equivalents
35.69
-59.09%
87.23
-6.32%
93.11
+113.63%
43.59
Cash Financial
—
—
—
—
Other Short Term Investments
65.39
+2.68%
63.69
+365.37%
13.69
-82.89%
79.98
Receivables
—
1.12
-54.59%
2.46
-62.05%
6.49
Taxes Receivable
—
0.00
-100.00%
2.02
-68.82%
6.49
Accrued Interest Receivable
—
1.12
+154.32%
0.44
—
Prepaid Assets
4.77
+20.64%
3.95
+348.69%
0.88
-33.76%
1.33
Other Current Assets
—
0.26
+128.57%
0.11
-96.27%
3.00
Total Non Current Assets
61.90
-0.67%
62.31
+29019.16%
0.21
-64.27%
0.60
Net PPE
0.79
+15.09%
0.69
+246.23%
0.20
-57.75%
0.47
Gross PPE
0.79
+15.09%
0.69
+246.23%
0.20
-57.75%
0.47
Other Properties
0.79
+15.09%
0.69
+246.23%
0.20
-57.75%
0.47
Investments And Advances
59.57
-3.31%
61.61
0.00
0.00
Other Non Current Assets
1.53
+9462.50%
0.02
+6.67%
0.01
-88.28%
0.13
Total Liabilities Net Minority Interest
7.27
+37.00%
5.31
+84.88%
2.87
-54.28%
6.28
Current Liabilities
6.98
+41.63%
4.93
+74.06%
2.83
-53.53%
6.10
Payables And Accrued Expenses
6.67
+42.35%
4.68
+98.43%
2.36
-59.27%
5.80
Payables
2.27
+221.84%
0.70
+968.18%
0.07
-91.20%
0.75
Accounts Payable
2.27
+221.84%
0.70
+968.18%
0.07
-91.20%
0.75
Current Accrued Expenses
4.40
+10.55%
3.98
+73.42%
2.29
-54.53%
5.05
Current Debt And Capital Lease Obligation
0.26
+63.06%
0.16
-52.99%
0.33
+11.33%
0.30
Current Capital Lease Obligation
0.26
+63.06%
0.16
-52.99%
0.33
+11.33%
0.30
Other Current Liabilities
0.06
-33.71%
0.09
-35.51%
0.14
—
Total Non Current Liabilities Net Minority Interest
0.28
-24.00%
0.38
+913.51%
0.04
-79.44%
0.18
Long Term Debt And Capital Lease Obligation
0.28
-24.00%
0.38
+2400.00%
0.01
-91.67%
0.18
Long Term Capital Lease Obligation
0.28
-24.00%
0.38
+2400.00%
0.01
-91.67%
0.18
Other Non Current Liabilities
—
—
0.02
—
Stockholders Equity
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Common Stock Equity
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Capital Stock
0.01
-28.57%
0.01
+133.33%
0.00
+0.00%
0.00
Common Stock
0.01
-28.57%
0.01
+133.33%
0.00
+0.00%
0.00
Preferred Stock
—
—
—
—
Share Issued
47.77
-28.98%
67.26
+142.80%
27.70
+4.26%
26.57
Ordinary Shares Number
47.77
-28.98%
67.26
+142.80%
27.70
+4.26%
26.57
Additional Paid In Capital
449.76
+1.82%
441.73
+67.59%
263.58
+5.46%
249.93
Retained Earnings
-289.73
-26.04%
-229.88
-47.38%
-155.98
-29.06%
-120.86
Gains Losses Not Affecting Retained Earnings
0.43
+1791.30%
0.02
+1250.00%
-0.00
+99.44%
-0.36
Other Equity Adjustments
0.43
+1791.30%
0.02
+1250.00%
-0.00
+99.44%
-0.36
Total Equity Gross Minority Interest
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Total Capitalization
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Working Capital
98.86
-34.06%
149.94
+39.58%
107.42
-16.27%
128.30
Invested Capital
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Total Debt
0.54
+1.69%
0.53
+52.44%
0.35
-27.29%
0.48
Capital Lease Obligations
0.54
+1.69%
0.53
+52.44%
0.35
-27.29%
0.48
Net Tangible Assets
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Tangible Book Value
160.47
-24.26%
211.88
+96.92%
107.60
-16.41%
128.72
Available For Sale Securities
59.57
-3.31%
61.61
—
—
Dueto Related Parties Current
—
—
—
—
Investmentin Financial Assets
59.57
-3.31%
61.61
0.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-54.36
-249.29%
-15.56
+24.45%
-20.60
+44.88%
-37.37
Cash Flow From Continuing Operating Activities
-54.36
-249.29%
-15.56
+24.45%
-20.60
+44.88%
-37.37
Net Income From Continuing Operations
-59.85
+19.01%
-73.90
-110.42%
-35.12
+22.38%
-45.24
Depreciation Amortization Depletion
0.10
0.00
—
—
Depreciation And Amortization
0.10
0.00
—
—
Other Non Cash Items
0.20
-99.61%
51.88
+12709.63%
0.41
-8.58%
0.44
Stock Based Compensation
8.05
+44.93%
5.56
-56.61%
12.81
+83.18%
6.99
Asset Impairment Charge
—
0.00
-100.00%
0.18
0.00
Operating Gains Losses
0.02
+142.86%
-0.04
+86.18%
-0.30
-174.51%
0.41
Net Foreign Currency Exchange Gain Loss
0.02
+142.86%
-0.04
+86.18%
-0.30
-174.51%
0.41
Change In Working Capital
-0.60
-135.39%
1.70
-54.89%
3.76
+1692.38%
0.21
Change In Prepaid Assets
-0.82
-142.02%
1.94
-73.65%
7.37
+679.89%
0.94
Change In Payables And Accrued Expense
1.94
+534.75%
0.30
+109.25%
-3.30
-1346.93%
-0.23
Change In Accrued Expense
0.37
-74.26%
1.45
+155.30%
-2.61
-714.82%
0.42
Change In Payable
1.56
+237.19%
-1.14
-66.18%
-0.69
-5.05%
-0.65
Change In Account Payable
1.56
+237.19%
-1.14
-66.18%
-0.69
-5.05%
-0.65
Change In Other Current Assets
-1.51
-657.00%
-0.20
-273.91%
0.12
+291.67%
-0.06
Change In Other Current Liabilities
-0.21
+40.69%
-0.35
+17.30%
-0.42
+5.59%
-0.45
Investing Cash Flow
2.83
+102.34%
-121.09
-275.54%
68.98
+100.29%
34.44
Cash Flow From Continuing Investing Activities
2.83
+102.34%
-121.09
-275.54%
68.98
+100.29%
34.44
Net PPE Purchase And Sale
-0.19
0.00
—
—
Purchase Of PPE
-0.19
0.00
—
—
Capital Expenditure
-0.19
—
—
—
Net Investment Purchase And Sale
3.02
+102.71%
-111.45
-261.56%
68.98
+100.29%
34.44
Purchase Of Investment
-108.08
+18.24%
-132.20
-126.17%
-58.45
+33.55%
-87.96
Sale Of Investment
111.10
+435.41%
20.75
-83.72%
127.43
+4.11%
122.40
Net Other Investing Changes
—
-9.64
—
—
Financing Cash Flow
-0.02
-100.02%
130.73
+15444.47%
0.84
0.00
Cash Flow From Continuing Financing Activities
-0.02
-100.02%
130.73
+15444.47%
0.84
0.00
Net Common Stock Issuance
0.00
-100.00%
119.75
0.00
0.00
Proceeds From Stock Option Exercised
0.07
-99.41%
10.98
+1205.47%
0.84
0.00
Net Other Financing Charges
-0.09
—
—
—
Changes In Cash
-51.54
-769.94%
-5.92
-112.04%
49.22
+1780.54%
-2.93
Effect Of Exchange Rate Changes
0.00
-100.00%
0.04
-86.18%
0.30
+174.51%
-0.41
Beginning Cash Position
87.23
-6.32%
93.11
+113.63%
43.59
-7.11%
46.92
End Cash Position
35.69
-59.09%
87.23
-6.32%
93.11
+113.63%
43.59
Free Cash Flow
-54.54
-250.48%
-15.56
+24.45%
-20.60
+44.88%
-37.37
Amortization Of Securities
-2.27
-200.40%
-0.76
+67.52%
-2.33
-1216.95%
-0.18
Common Stock Issuance
0.00
-100.00%
119.75
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
119.75
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category